Jennifer Spokes Johansson has more than 20 years of pharmaceutical legal and regulatory experience. She is currently the Vice President of Regulatory Affairs and Counsel at Chondrial Therapeutics. Most recently, Jennifer served as the senior Vice President of Regulatory Policy and Counsel for Putney, Inc., where she was chair of the Generic Animal Drug Alliance and a member of the industry negotiation teams for the Animal Generic Drug User Fee Act and its reauthorization. Jennifer also served as Vice President of Regulatory Affairs and Counsel for Andrx (now Teva), the largest generic drug company in the world.
Before joining Andrx, she worked at the law firm of Patton Boggs (now Squire Patton Boggs) as an associate in a leading food and drug regulatory practice. Jennifer completed her undergraduate career at Duke University, where she graduated cum laude and with Distinction in Biology. She continued her education at Boston University School of Law and, while there, served as an editor of the Boston University Law Review and graduated magna cum laude. She is a member of the bars of Massachusetts and Washington, DC.